Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 12:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 1,237 matching trials from the live ClinicalTrials.gov search.
Conditions
Epilepsy, Epilepsy in Youth, Activities, Daily Living
Interventions
Surviving and Thriving in the Real World
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
14 Years to 19 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Epilepsy, Temporal Lobe
Interventions
LIFUP
Device
Lead sponsor
BrainSonix Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Recruiting No phase listed Observational

Physiological Brain Atlas Development

NCT00575081
Conditions
Parkinson's Disease, Obsessive Compulsive Disorder, Dystonia, Essential Tremor, Epilepsy
Interventions
Stereotactic brain procedures
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
6 Years to 90 Years
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Lennox Gastaut Syndrome
Interventions
Carisbamate
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
2 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
5
States / cities
Baltimore, Maryland • Lebanon, New Hampshire • Portland, Oregon + 2 more
Completed Phase 1Phase 2 Interventional Results available

Dosing of Levetiracetam (Keppra) in Neonates

NCT01239212
Conditions
Seizures
Interventions
levetiracetam
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Day to 30 Days
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Social Influence, Epilepsy
Interventions
Low social feedback, High social feedback
Behavioral
Lead sponsor
Trustees of Dartmouth College
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Lebanon, New Hampshire
Conditions
Epilepsy
Interventions
Levetiracetam
Drug
Lead sponsor
UCB Pharma SA
Industry
Eligibility
1 Month to 4 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
San Diego, California • Buffalo, New York • Philadelphia, Pennsylvania + 3 more
Completed Not applicable Interventional

HOBSCOTCH Phase II

NCT02394509
Conditions
Epilepsy
Interventions
Home Based Self-management and Cognitive Training Changes lives (HOBSCOTCH)
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
4
States / cities
Portland, Maine • Worcester, Massachusetts • Lebanon, New Hampshire + 1 more
Conditions
Psychogenic Nonepileptic Seizures (PNES)
Interventions
Cognitive Rehabilitation And Functional Treatment (CRAFT)
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Providence, Rhode Island
Conditions
Epilepsy, Alzheimer Disease, Epilepsy Intractable
Interventions
NPT 2042 (bumetanide analog) or Matching Placebo
Drug
Lead sponsor
NeuroPro Therapeutics, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lincoln, Nebraska
Conditions
Keratoconus, Ocular Surface Disease, Pellucid Marginal Corneal Degeneration, Ectasia, Corneal Trauma, Corneal Scar, Dry Eye Syndromes, Keratoconjunctivitis Sicca, Sjogren's Syndrome
Interventions
Ocular surface optical coherence tomography
Device
Lead sponsor
Boston Sight
Other
Eligibility
21 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Needham, Massachusetts
Conditions
Neuroblastoma
Interventions
LY3295668 Erbumine, Topotecan, Cyclophosphamide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
2 Years to 21 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
San Francisco, California • Aurora, Colorado • Chicago, Illinois + 4 more
Conditions
Dentatorubral-Pallidoluysian Atrophy
Interventions
nL-ATN1-002
Drug
Lead sponsor
n-Lorem Foundation
Other
Eligibility
29 Years to 29 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Honolulu, Hawaii
Conditions
Drug Resistant Partial Onset Seizure
Interventions
ganaxolone
Drug
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Santa Monica, California • Lexington, Kentucky • Golden Valley, Minnesota + 2 more
Conditions
Infantile Spasms, Non-Intractable
Interventions
Remote monitoring
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
31 Days to 30 Months
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Focal Onset Seizure
Interventions
Cenobamate
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
19
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 15 more
Conditions
Epilepsy
Interventions
Lacosamide Tablet, Lasosamide Oral Solution, Placebo Tablet, Placebo Oral Solution
Drug · Other
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
4 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
27
States / cities
Alabaster, Alabama • Little Rock, Arkansas • Irvine, California + 23 more
Conditions
Dravet Syndrome (DS)
Interventions
Soticlestat, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
2 Years to 21 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 7 more
Completed Phase 1Phase 2 Interventional Results available

Determination of Absorption and Elimination of Lamotrigine-XR

NCT00789113
Conditions
Epilepsy, Seizures, Bipolar Disorder, Bipolar Depression
Interventions
Extended Release Lamotrigine
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
65 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Major Depressive Disorder
Interventions
Magstim Theta, Thymatron System IV
Device
Lead sponsor
Sarah Lisanby
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
2
States / cities
Durham, North Carolina • Dallas, Texas
Conditions
Mild Cognitive Impairment (MCI), Alzheimer Disease (AD), Dementia With Lewy Bodies (DLB), Frontotemporal Lobar Degeneration (FTLD), Parkinsons Disease With Dementia (PDD), Transient Epileptic Amnesia (TEA), Temporal Lobe Epilepsy (TLE), Spinocerebellar Ataxias (SCA), HIV Associated Neurocognitive Disorder (HAND), Amyotrophic Lateral Sclerosis (ALS), Primary Lateral Sclerosis (PLS)
Interventions
Neuraceq
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Timeline
2019 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Epilepsy
Interventions
oxygen
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Recruiting Not applicable Interventional

Optimizing Brain Stimulation Parameters

NCT06617845
Conditions
Epilepsy; Seizure
Interventions
Stimulation Set A and B
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
6 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Completed No phase listed Observational Accepts healthy volunteers

Serotonin Receptors in Seizure Disorders

NCT00001932
Conditions
Partial Epilepsy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 60 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland